Welcome to our dedicated page for Navidea Biopharm news (Ticker: NAVB), a resource for investors and traders seeking the latest updates and insights on Navidea Biopharm stock.
Navidea Biopharmaceuticals, Inc. reports developments tied to its biopharmaceutical platform, corporate status, and capital structure. The company focuses on precision immunodiagnostic agents and immunotherapeutics built around the Manocept platform, which targets the CD206 mannose receptor expressed on activated macrophages. Its disclosed programs include Tc99m tilmanocept and clinical work in rheumatoid arthritis, along with a stated focus on therapeutic assets.
Navidea news also covers Chapter 11, Subchapter V bankruptcy proceedings, OTC trading status, voluntary SEC deregistration actions, reverse stock split authority, Section 382 rights plan matters related to tax assets, litigation settlements, special stockholder meetings, and board changes. These updates place the company’s product-development strategy alongside recurring disclosure themes involving governance, financing, reporting obligations, and corporate restructuring.
Navidea (NASDAQ:NAVB) filed a voluntary petition under Chapter 11, Subchapter V in the U.S. Bankruptcy Court for the District of Delaware on October 1, 2025. The company said the filing is intended to enable an orderly restructuring of financial obligations while continuing limited operations to preserve value for creditors and stakeholders. Navidea plans to use the Chapter 11 process to evaluate strategic alternatives, protect assets, and ensure fair treatment of creditors. Epiq Corporate Restructuring is serving as claims and noticing agent and case materials are available at https://dm.epiq11.com/Navidea.
Navidea Biopharmaceuticals (NAVB) has announced the extension of its Section 382 Rights Agreement from April 6, 2025, to April 7, 2027. This strategic move aims to protect approximately $170 million in U.S. federal NOLs and $9 million in R&D tax credits that could offset future taxable income.
The Rights Plan prevents an 'ownership change' under Section 382 of the Internal Revenue Code by discouraging any person or group from acquiring 4.99% or more of Navidea's outstanding common stock. If triggered, existing shareholders can purchase shares at a 50% discount or receive five shares for each right, excluding the acquiring party.
The company originally implemented this plan on April 7, 2022, declaring one preferred share purchase right per common stock outstanding as of April 12, 2022. The Board maintains discretion to grant exemptions to this plan.
Navidea Biopharmaceuticals, a company specializing in precision immunodiagnostic agents and immunotherapeutics, announced the disappointing results of an exploratory analysis for their NAV3-33 clinical trial. This trial aimed to evaluate the efficacy of Tc 99m tilmanocept imaging in predicting early responses to anti-TNFα therapy for rheumatoid arthritis (RA). The analysis, completed on July 2, 2024, showed that while the imaging technique could reliably target macrophage activity, it failed to accurately predict treatment responses, with accuracy consistently below 70%, far from the anticipated 90%. Consequently, Navidea will suspend activities related to this RA trial and shift focus to other therapeutic assets.
Navidea Biopharmaceuticals announced a virtual special meeting of stockholders on July 8, 2024, to vote on two proposals. The first proposal is an amendment to the company's certificate of incorporation to allow stockholders to act by written consent. The second proposal is to implement a reverse stock split of the company's common stock at a ratio of up to 1-for-50,000 shares. The final decision regarding the reverse stock split will be determined by the Board of Directors. Navidea's CFO, Craig A. Dais, highlighted the importance of these measures in pursuing strategic partnerships and reducing costs. Additionally, three directors resigned from the board, and the company terminated its executive consulting agreement with G2G Ventures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.